Literature DB >> 18926701

Paclitaxel succinate analogs: Anionic and amide introduction as a strategy to impart blood-brain barrier permeability.

Brandon J Turunen1, Haibo Ge, Jariat Oyetunji, Kelly E Desino, Veena Vasandani, Sarah Güthe, Richard H Himes, Kenneth L Audus, Anna Seelig, Gunda I Georg.   

Abstract

A focused library of TX-67 (C10 hemi-succinate) analogs has been prepared, including C7 regioisomers, esters, amides, and one-carbon homologs. These were prepared to investigate whether the lack of TX-67 interaction with P-glycoprotein (Pgp) is due to the presence of the carboxylic acid moiety and whether this phenomenon was restricted to C10 analogs. Tubulin stabilization ability, cytotoxicity, and Pgp interactions were evaluated. All carboxylic acid analogs and several of the amides had no apparent interactions with Pgp at the concentrations used, whereas the ester variants displayed characteristics of Pgp substrates. Furthermore, it was demonstrated that hydrogen-bonding properties were significant with respect to Pgp interactions. Calculations of logD and cross-sectional areas revealed that these analogs are predicted to partition into the membrane and can compete for Pgp binding sites. The anionic and amide introduction strategy may allow for delivery of paclitaxel into the CNS and may be a potential approach for the delivery of other, structurally complex and lipophilic non-CNS permeable drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926701      PMCID: PMC2634772          DOI: 10.1016/j.bmcl.2008.09.103

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  18 in total

1.  Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.

Authors:  Guibin Li; Alexander Faibushevich; Brandon J Turunen; Sung Ok Yoon; Gunda Georg; Mary L Michaelis; Rick T Dobrowsky
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

2.  Quantification and characterization of P-glycoprotein-substrate interactions.

Authors:  Ewa Gatlik-Landwojtowicz; Päivi Aänismaa; Anna Seelig
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

Review 3.  Structure-brain exposure relationships.

Authors:  Stephen A Hitchcock; Lewis D Pennington
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

4.  Blood-brain barrier permeation: molecular parameters governing passive diffusion.

Authors:  H Fischer; R Gottschlich; A Seelig
Journal:  J Membr Biol       Date:  1998-10-01       Impact factor: 1.843

5.  Evaluation of the role of P-glycoprotein in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells.

Authors:  J M Rose; S L Peckham; J L Scism; K L Audus
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

Review 6.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

7.  Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison.

Authors:  A Seelig; X L Blatter; F Wohnsland
Journal:  Int J Clin Pharmacol Ther       Date:  2000-03       Impact factor: 1.366

8.  Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells.

Authors:  Haibo Ge; Veena Vasandani; Jacquelyn K Huff; Kenneth L Audus; Richard H Himes; Anna Seelig; Gunda I Georg
Journal:  Bioorg Med Chem Lett       Date:  2005-11-03       Impact factor: 2.823

9.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Authors:  A Sparreboom; J van Asperen; U Mayer; A H Schinkel; J W Smit; D K Meijer; P Borst; W J Nooijen; J H Beijnen; O van Tellingen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

10.  Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

Authors:  E Marleen Kemper; A Erik van Zandbergen; Cindy Cleypool; Henk A Mos; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

View more
  7 in total

Review 1.  Analytical and biological methods for probing the blood-brain barrier.

Authors:  Courtney D Kuhnline Sloan; Pradyot Nandi; Thomas H Linz; Jane V Aldrich; Kenneth L Audus; Susan M Lunte
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2012       Impact factor: 10.745

2.  Recombinant Synthesis of Hybrid Lipid-Peptide Polymer Fusions that Self-Assemble and Encapsulate Hydrophobic Drugs.

Authors:  Kelli M Luginbuhl; Davoud Mozhdehi; Michael Dzuricky; Parisa Yousefpour; Fred C Huang; Nicholas R Mayne; Kristen L Buehne; Ashutosh Chilkoti
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-09       Impact factor: 15.336

3.  Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation.

Authors:  John M Ndungu; Yang J Lu; Shijun Zhu; Chao Yang; Xu Wang; Georgia Chen; Dong M Shin; James P Snyder; Mamoru Shoji; Aiming Sun
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

4.  17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease.

Authors:  Ferdinando Nicoletti; Ingrid Philippens; Paolo Fagone; Clarence N Ahlem; Christopher L Reading; James M Frincke; Dominick L Auci
Journal:  Parkinsons Dis       Date:  2012-09-26

Review 5.  Blood brain barrier: a challenge for effectual therapy of brain tumors.

Authors:  Arijit Bhowmik; Rajni Khan; Mrinal Kanti Ghosh
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

6.  A luciferase prosubstrate and a red bioluminescent calcium indicator for imaging neuronal activity in mice.

Authors:  Xiaodong Tian; Yiyu Zhang; Xinyu Li; Ying Xiong; Tianchen Wu; Hui-Wang Ai
Journal:  Nat Commun       Date:  2022-07-08       Impact factor: 17.694

7.  Hempseed Lignanamides Rich-Fraction: Chemical Investigation and Cytotoxicity towards U-87 Glioblastoma Cells.

Authors:  Ersilia Nigro; Giuseppina Crescente; Marialuisa Formato; Maria Tommasina Pecoraro; Marta Mallardo; Simona Piccolella; Aurora Daniele; Severina Pacifico
Journal:  Molecules       Date:  2020-02-26       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.